According to Zacks, “Caladrius Biosciences, Inc. is an immunotherapy company which specializes in cell process optimization, development and manufacturing. Its product candidate consists of NBS20, a targeted cancer immunotherapy product for the treatment of metastatic melanoma; NBS10, an ischemic repair product to preserve heart muscle function following an acute myocardial infarction and NBS03D, an immune modulation product for the treatment of diabetes which are in different clinical trials. Caladrius Biosciences, Inc., formerly known as NeoStem, Inc., is headquartered in New York. “
Separately, Chardan Capital restated a buy rating and set a $6.50 price objective on shares of Caladrius Biosciences in a research report on Wednesday, November 9th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company has an average rating of Buy and a consensus price target of $4.83.
Caladrius Biosciences (NASDAQ:CLBS) traded up 0.26% during trading on Tuesday, hitting $3.88. The stock had a trading volume of 22,642 shares. Caladrius Biosciences has a one year low of $2.65 and a one year high of $13.30. The stock has a 50 day moving average of $3.49 and a 200 day moving average of $4.61.
Caladrius Biosciences (NASDAQ:CLBS) last announced its quarterly earnings data on Monday, November 7th. The company reported ($1.09) earnings per share for the quarter, topping the consensus estimate of ($1.55) by $0.46. Caladrius Biosciences had a negative return on equity of 270.38% and a negative net margin of 183.36%. On average, equities research analysts expect that Caladrius Biosciences will post ($5.06) EPS for the current year.
A number of institutional investors have recently modified their holdings of CLBS. Knoll Capital Management LP bought a new stake in shares of Caladrius Biosciences during the third quarter valued at $266,000. Eagle Global Advisors LLC bought a new stake in shares of Caladrius Biosciences during the third quarter valued at $127,000. Hollencrest Securities LLC bought a new stake in shares of Caladrius Biosciences during the third quarter valued at $570,000. Finally, Vanguard Group Inc. boosted its stake in shares of Caladrius Biosciences by 1.6% in the second quarter. Vanguard Group Inc. now owns 1,325,847 shares of the company’s stock valued at $783,000 after buying an additional 20,424 shares during the last quarter. 20.92% of the stock is owned by institutional investors and hedge funds.
About Caladrius Biosciences
Caladrius Biosciences, Inc, formerly NeoStem, Inc, through its subsidiary, PCT, LLC, a Caladrius Company (PCT), provides development and manufacturing services to the cell therapy industry (which includes cell-based gene therapy). PCT specializes in cell and cell-based gene therapies. PCT offers development and manufacturing capabilities, quality systems, cell and tissue processing, logistics, storage and distribution and engineering solutions to clients with therapeutic candidates at all stages of development.
Receive News & Ratings for Caladrius Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences Inc. and related companies with our FREE daily email newsletter.